No Data
No Data
Zhejiang Huahai Pharmaceutical (600521.SH): Currently has no production capacity in the field of vitamins.
Zhejiang Huahai Pharmaceutical (600521.SH) stated on the interactive platform on August 8 that the company currently has no production capacity in the field of vitamins.
Zhejiang Huahai Pharma Gets China Registration Approval for Rhinitis, Diabetes Drugs
Huahai Pharmaceutical (600521.SH): Rupatadine fumarate tablets and vilgliptin tablets obtained drug registration certificates
On August 6th, Gelunhui reported that Zhejiang Huahai Pharmaceutical (600521.SH) recently received the Drug Registration Certificate for Fumarate Loratadine Tablets and Voglibose Tablets issued by the State Drug Administration. Fumarate Loratadine Tablets are used for symptomatic treatment of allergic rhinitis and urticaria in adults and adolescents (over 12 years old). Voglibose Tablets are used to treat type 2 diabetes.
Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Market Cap Dropped CN¥1.2b Last Week; Retail Investors Bore the Brunt
Huahai Pharmaceutical's Unit Gets Registration Nod for Levetiracetam Oral Solution
Zhejiang Huahai Pharmaceutical (600521.SH): Registration certificate obtained for pharmaceutical oral solution of levetiracetam.
On July 19, Gelun Hui reported that its subsidiary, Changxing Pharmaceutical Co., Ltd., received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for oral solution of Levetiracetam. The oral solution is mainly used as an adjunctive treatment for partial seizures in adult, pediatric and infants over one month old with epilepsy.
No Data